HPV Vaccination in Women With Cystic Fibrosis (VACCIN-HPV-MUC)

Civil Hospices of Lyon

Status: Completed

Conditions: Human Papillomavirus Infection

Treatments: Other: Self-report Written Questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT03265743

69HCL17_0277

Details and patient eligibility

About

The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France.

Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population.

The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.

Enrollment: 74 patients

Sex: Female

Ages: 11 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• girls with Cystic Fibrosis
• followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA)
• aged 11 years or older

Exclusion criteria

• Refusal to respond to the questionnaire

Trial design

74 participants in 1 patient group

Patients with Cystic Fibrosis

Description:

Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.

Treatment:

Other: Self-report Written Questionnaire